- Date 03 February 2016
- Documents : 4
- Economic analysis
- History
Listen
OPDIVO (nivolumab), anti-PD-1 antibody
TRANSPARENCY COMMITTEE OPINION
Opinions on drugs -
Posted on
Dec 21 2017
Reason for request
Extension of inclusion
Moderate improvement in the treatment of squamous, locally advanced or metastatic non-small cell lung cancer after prior chemotherapy
- OPDIVO has Marketing Authorisation in monotherapy in the treatment of adults with squamous, locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.
- It improves median overall survival by 3.2 months compared with docetaxel in patients with failure of platinum salt-based chemotherapy.
- This is a second-line of NSCLC
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| moderate |
- |
-
Economic analysis
English version
Contact Us
Évaluation des médicaments
